!!Philip Scheltens - Selected Publications
\\
668 peer reviewed publications (updated from PUBMED 27-2-15).\\
H-factor 84 (web of science 01-03-15)\\
\\
\\
1: Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Morbelli S, Frisoni GB, Drzezga A, Didic M, van Berckel BN, Simmons A, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Muscio C, Herukka SK, Salmon E, Bastin C, Wallin A, Nordlund A, de Mendonça A, Silva D, Santana I, Lemos R, Engelborghs S, Van der Mussele S; The Alzheimer’s\\
Disease Neuroimaging Initiative, Freund-Levi Y, Wallin ÅK, Hampel H, van der Flier W, Scheltens P, Visser PJ. Prevalence and prognosis of Alzheimer's disease  at the mild cognitive impairment stage. Brain. 2015 Feb 17. \\
IF=10.22\\
\\
2: Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. \\
IF=21.82\\
\\
3: Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H  Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO,  Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D,  Blankenstein MA, Scheltens P, van der Flier WM. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimers Dement. 2014  Nov;10(6):713-723.e2. \\
IF=17.47\\
\\
4: van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, Scheltens P, van der Flier WM. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013 Oct 15;81(16):1409-16. \\
IF=8.30\\
\\
5: Scheltens P. Dementia: Mild cognitive impairment--amyloid and beyond. Nat Rev  Neurol. 2013 Sep;9(9):493-5.  \\
IF=14.10\\
\\
6: Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow  K, Wolz R, Scheltens P, Visser PJ. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. 2013 Mar 19;80(12):1124-32. \\
IF=8.30\\
\\
7: van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM. Cerebrospinal fluid Aβ42 is the best predictor of  clinical progression in patients with subjective complaints. Alzheimers Dement.\\
2013 Sep;9(5):481-7.  \\
IF=17.472\\
\\
8: Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, Gillissen F, Romkes R, Knol DL, Uitdehaag BM, Scheltens P. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 2012 Nov;8(6):536-43.  IF=17.472\\
\\
9. Van der Flier WM, pijnenburg YA, Fox NC, Scheltens P. Early onset vs late onset Alzheimer's disease: the case of the missing APOE4 gene. Lancet Neurology 2011 Mar;10(3):280-8. \\
IF=21.82\\
\\
10: Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA,Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010 Nov;9(11):1118-27.  IF=21.82